Literature DB >> 31912959

Investigation of de novo variation in pediatric cardiomyopathy.

Ashley Parrott1, Philip R Khoury1, Amy R Shikany1, Angela Lorts1, Chet R Villa1, Erin M Miller1.   

Abstract

Pediatric cardiomyopathies can be caused by variants in genes encoding the sarcomere and cytoskeleton in cardiomyocytes. Variants are typically inherited in an autosomal dominant manner with variable expressivity. De novo variants have been reported, however their overall frequency is largely unknown. We sought to determine the rate of de novo, pathogenic and likely pathogenic (P/LP) variants in children with a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy (HCM, DCM, or RCM), and to compare disease outcomes between individuals with and without a de novo variant. A retrospective record review identified 126 individuals with HCM (55%), DCM (37%), or RCM (8%) ≤18 years of age who had genetic testing. Overall, 50 (40%) had positive genetic testing and 18% of P/LP variants occurred de novo. The rate of de novo variation in those with RCM (80%) was higher than in those with HCM (9%) or DCM (20%). There was evidence of germline mosaicism in one family with RCM. Individuals with de novo variants were more likely than those without to have a history of arrhythmia (p = .049), sudden cardiac arrest (p = .024), hospitalization (p = .041), and cardiac transplantation (p = .030). The likelihood of de novo variation and impact on family risk and screening should be integrated into genetic counseling.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiomyopathy; de novo; mosaicism; pediatric

Mesh:

Year:  2020        PMID: 31912959     DOI: 10.1002/ajmg.c.31764

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  2 in total

1.  The clinical utility of pediatric cardiomyopathy genetic testing: From diagnosis to a precision medicine-based approach to care.

Authors:  Lauren E Parker; Andrew P Landstrom
Journal:  Prog Pediatr Cardiol       Date:  2021-07-01

2.  Pediatric Primary Dilated Cardiomyopathy Gene Testing and Variant Reclassification: Does It Matter?

Authors:  Jeffrey A Towbin
Journal:  J Am Heart Assoc       Date:  2020-05-27       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.